Bacterial colonization of the urogenital tract is limited by innate defenses, including the production of antimicrobial peptides (AMPs). Uropathogenic Escherichia coli (UPEC) resist AMP-killing to cause a range of urinary tract infections (UTIs) including asymptomatic bacteriuria, cystitis, pyelonephritis, and sepsis. UPEC strains have high genomic diversity and encode numerous virulence factors that differentiate them from non-UTI-causing strains, including ompT. As OmpT homologs cleave and inac-
tivate AMPs, we hypothesized that UPEC strains from patients with symptomatic UTIs have high OmpT protease activity. Therefore, we measured OmpT activity in 58 clinical E. coli isolates. While heterogeneous OmpT activities were observed, OmpT activity was significantly greater in UPEC strains isolated from patients with symptomatic infections. Unexpectedly, UPEC strains exhibiting the greatest protease activities harbored an additional ompT-like gene called arlC (ompTp). The presence of two OmpT-like proteases in some UPEC isolates led us to compare the substrate specificities of OmpT-like proteases found in E. coli. While all three cleaved AMPs, cleavage efficiency varied on the basis of AMP size and secondary structure. Our findings suggest the presence of ArlC and OmpT in the same UPEC isolate may confer a fitness advantage by expanding the range of target substrates.
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| INTRODUC TI ON
Urinary tract infections (UTIs) are among the most common cause of bacterial infections requiring antibiotic treatment (Flores-Mireles, Walker, Caparon, & Hultgren, 2015; Foxman, 2014; Hooton & Stamm, 1997) . The majority of community-acquired UTIs (70%-95%) and recurrent UTIs are caused by uropathogenic Escherichia coli (UPEC) (Flores-Mireles et al., 2015; Nielubowicz & Mobley, 2010) . The human gut acts as a reservoir for UPEC strains where they form part of the fecal flora (Kaper, Nataro, & Mobley, 2004; Moreno et al., 2006) .
Following colonization of the periurethral area, UPEC infect the urinary tract in an ascending manner, resulting in diseases ranging from asymptomatic bacteriuria (ABU), cystitis, pyelonephritis, and sepsis (Hooton, 2012) . UPEC strains have high genomic diversity and encode numerous virulence factors that differentiate them from non-UTIcausing strains (Johnson, 1991; Lloyd, Rasko, & Mobley, 2007; Najafi, Hasanpour, Askary, Aziemzadeh, & Hashemi, 2018; Norinder, Koves, Yadav, Brauner, & Svanborg, 2012) . These virulence factors contribute to disease progression allowing UPEC to colonize the uroepithelium, produce toxins, scavenge metabolites, and evade the host immune system (Schwab, Jobin, & Kurts, 2017; Terlizzi, Gribaudo, & Maffei, 2017) .
Bacterial colonization is limited in the upper urogenital tract by several mechanisms including urine flow, chemical properties of urine, epithelial cell shedding, influx of immune cells including neutrophils upon bacterial stimulation, and secretion of soluble proteins and peptides by epithelial cells (Spencer, Schwaderer, Becknell, Watson, & Hains, 2014; Weichhart, Haidinger, Horl, & Saemann, 2008) . Secreted proteins and antimicrobial peptides (AMPs) form part of the innate immune defenses of the urogenital tract and act through immunomodulation, indirect anticolonization activity, or direct bacterial killing (Kai-Larsen et al., 2010; Zasloff, 2007) . AMPs are small (12-50 amino acids), cationic, amphipathic peptides that exert bactericidal action by interacting with anionic bacterial membranes to form pores resulting in bacterial lysis (Jenssen, Hamill, & Hancock, 2006) . Two types of AMPs are detected in the urogenital tract: defensins that form small disulfide bond-stabilized ß-sheets and the α-helical cathelicidin LL-37 (Chromek et al., 2006; Lehmann et al., 2002; Valore et al., 1998) . In addition, the urogenital tract produces large structured antimicrobial proteins called ribonucleases (RNases) (Spencer et al., 2011 (Spencer et al., , 2013 . Human α-defensin 5 (HD5), human ß-defensins (hBD) 1 and 2, LL-37, and RNase 7 are thought to prevent bacterial colonization as they are constitutively expressed in the urinary tract (Kjolvmark, Akesson, & Pahlman, 2017; Spencer et al., 2012) . During UTIs, production of HD5, hBD2, LL-37, and RNase 7 increases, suggesting an active role in bacterial clearance (Chromek & Brauner, 2008; Chromek et al., 2006; Nielsen et al., 2014; Spencer et al., 2012 Spencer et al., , 2013 . Remarkably, increased cathelicidin expression and LL-37 secretion are triggered a few minutes after bacteria encounter uroepithelial cells. This suggested role for AMPs in UTI immune defense is consistent with reports that UPEC strains are generally more resistant to AMPs than commensal E. coli strains that do not colonize the urogenital tract (Chromek et al., 2006) .
Gram-negative bacteria use several mechanisms to resist killing by AMPs, including capsules, efflux pumps, LPS modifications, and proteases . Omptin proteases are found in the Gram-negative outer bacterial membrane and have a conserved active site with features of both aspartate and serine proteases Vandeputte-Rutten et al., 2001) . With their active sites facing the extracellular environment, omptins contribute to virulence by cleaving a variety of proteins and peptides (Haiko, Suomalainen, Ojala, Lahteenmaki, & Korhonen, 2009 ). Both substrate specificity and amino acid identity are used to classify omptins into Pla-like and OmpT-like subfamilies. Pla readily cleaves the proenzyme plasminogen into active plasmin to promote bacterial dissemination during both bubonic and pneumonic plague (Lathem, Price, Miller, & Goldman, 2007; Sodeinde et al., 1992; Zimbler, Schroeder, Eddy, & Lathem, 2015) . OmpT rapidly cleaves and inactivates AMPs, including LL-37, protamine, and a synthetic peptide optimized to have maximum antibacterial activity called C18G (Brannon, Thomassin, Desloges, Gruenheid, & Le Moual, 2013; Stumpe, Schmid, Stephens, Georgiou, & Bakker, 1998; Thomassin, Brannon, Gibbs, Gruenheid, & Le Moual, 2012) . OmpT-mediated AMP inactivation is thought to support host colonization by some pathogenic E. coli strains (Thomassin, Brannon, Gibbs, et al., 2012) . In addition to OmpT, two OmpT-like proteases have been described in E. coli strains (Kaufmann, Stierhof, & Henning, 1994; McPhee et al., 2014; Zhuge et al., 2018) ; these genes, called ompP and arlC (ompTp), encode proteins that have approximately 74% amino acid identity to OmpT (GenBank accession numbers:
AAC73666.1 (OmpT), BAA97899.1 (OmpP), ADR30001.1 (ArlC)). While the physiological substrates of OmpP and ArlC are unknown, OmpP has been shown to cleave the AMP protamine and ArlC is associated with AMP resistance (Hwang et al., 2007; McPhee et al., 2014) .
The ompT gene is present in the genome of 85%-97% of UPEC clinical isolates and is used in epidemiological studies to identify virulent UPEC strains, yet its function across clinical isolates remains unclear (Foxman, Zhang, Palin, Tallman, & Marrs, 1995) . As OmpT and
OmpT-like omptins play roles in resistance to host-produced AMPs, we hypothesized that UPEC strains from patients with symptomatic UTIs have high OmpT protease activity. To test this hypothesis, we detected ompT and measured OmpT activity in a collection of 58 clinical E. coli isolates from groups of patients with infections of differing clinical severity (fecal, ABU, UTI [cystitis and pyelonephritis], and sepsis).
Heterogeneous OmpT activity was observed, and in some isolates, high protease activity was correlated with the presence of an additional ompT-like gene called arlC (ompTp). The presence of two OmpTlike proteases in some UPEC isolates led us to compare the substrate specificity of the three E. coli omptins (OmpT, OmpP, and ArlC). We found that OmpT, OmpP, and ArlC all cleave AMPs, although cleavage efficiency of different AMP types varied. Our results suggest that the presence of multiple omptins allows UPEC to cleave at least two major subsets of AMPs encountered during infection.
| Multiplex PCR of UPEC virulence genes
Total DNA (genomic and large plasmid DNA) was isolated using the Puregene Yeast/Bact. kit (Qiagen). Phylogenetic groups were determined as described in Clermont, Bonacorsi, and Bingen (2000) , using primer pairs listed in Table 2 . To detect virulence genes present in the isolates, primer sequences were obtained from previous studies (Johnson & Stell, 2000) or designed de novo for this study (Table 2) . Three multiplex PCR experiments were performed as follows: pool 1: hylA (1,177 bp), papAH (720 bp), fimH (508 bp), kpsMTIII (392 bp), and papEF (336 bp); pool 2: papC (200 bp), sfaS (240 bp), cnf1 (498 bp), fyuA (880 bp), iutA (300 bp), and kpsMTII (272 bp); pool 3: arlC (852 bp), ompT (670 bp), fimH (508 bp), and ompP (648 bp).
| Fluorescence resonance energy transfer (FRET) activity assay
The FRET substrate containing a dibasic motif (RK) in its center (2Abz-SLGRKIQI-K(Dnp)-NH2) was purchased from Anachem. Bacteria were grown in N-minimal medium to mid-exponential phase and normalized to an OD 595nm of 0.5. Bacterial cells were pelleted and resuspended in phosphate-buffered saline (PBS 
| Plasmid construction
The ompT and arlC genes were PCR-amplified from DNA isolated from the UPEC UTI clinical isolate 6, also called cystitis 6, using their respective primer pairs ompT_cf/ompT_cr and arlC_cf/arlC_cr (Table 2) . PCR fragments were treated with XbaI and SacI and ligated into plasmid pWSK129 treated with the same enzymes, generating plasmids pWSKompT and pWSKarlC (Table 1) . The ompP gene was PCR-amplified from XL1-Blue DNA using primer pair ompP_cf/ ompP_cr. PCR products were treated with XbaI and PstI and ligated into pWSK129 treated with the same enzymes to generate plasmid pWSKompP. The pla gene under control of the croP promoter was subcloned from pYCpla (Brannon, Burk, et al., 2015) using XbaI and SacI and ligated into pWSK129 previously treated with the same enzymes, generating pWSKpla.
| Southern blotting
Total DNA was isolated and treated with EcoRV. Southern blotting and hybridization were performed as previously described (Taylor, Ouimet, Wargachuk, & Marczynski, 2011) using Hybond-XL membranes. Probes for ompT and arlC were PCR-generated using primer pairs ompT_sf/ ompT_sr and arlC_sf/arlC_sr, respectively (Table 2) . Probes were radiolabeled with dATP [α-32P] using the RadPrime kit (Invitrogen). The pWSKarlC plasmid was used as the positive control for the arlC probe.
| Quantitative RT-PCR
Quantitative RT-PCR (qPCR) was performed as previously described (Thomassin, Brannon, Gibbs, et al., 2012) . Briefly, bacterial strains were grown to an OD 595nm of 0.5 in N-minimal medium. Total RNA was isolated using TRIzol reagents (Invitrogen) and treated with TURBO DNase I (Ambion) to remove residual DNA. The absence of DNA was confirmed by qPCR using the primer pair rpoD_qf/ rpoD_qr. RNA (100 ng) was reverse-transcribed using Superscript II (Invitrogen) with 0.5 μg of random hexamer primers. A reaction mixture without Superscript II was also included and was used as the negative control. qPCRs were performed in a Rotor-Gene 3,000 thermal cycler (Corbett Research) using the Maxima SYBR Green qPCR kit (Thermo Scientific), according to the manufacturer's instructions. Primers used are listed in Table 2 . The relative expression levels were calculated by normalizing the threshold cycle (C T ) of ompT and arlC transcripts to the C T of rpoD using the 2 -ΔCT method (Livak & Schmittgen, 2001 ).
| Whole-genome sequencing
Sequencing was performed on a PacBio platform (Pacific Biosciences).
Genomic DNA samples were purified using the Gentra® Puregene® kit (Qiagen) and sheared to 20 kb using g-tubes (Covaris). Libraries were prepared using the template preparation kit from Pacific Biosciences. A single SMRT cell was sequenced to generate datasets including unique subreads with a minimum length of 3 kb. Genome assemblies of sequence reads were generated using a combination of HGAP/Celera/Quiver following Pacific Biosciences recommendations. The complete chromosome and plasmid sequences were submitted to GenBank. The BioProject accession numbers are as Coded as asymptomatic bacteriuria 1 (Manges, Johnson, et al., 2004) 10003U002 Coded as asymptomatic bacteriuria 2 (Manges, Johnson, et al., 2004) 10004U001 Coded as asymptomatic bacteriuria 3 (Manges, Johnson, et al., 2004) 10013U005 Coded as asymptomatic bacteriuria 4 (Manges, Johnson, et al., 2004) 10014U005 Coded as asymptomatic bacteriuria 5 (Manges, Johnson, et al., 2004) 10017U005 Coded as asymptomatic bacteriuria 6 (Manges, Johnson, et al., 2004) 1,001006 Coded as asymptomatic bacteriuria 7 (Manges, Johnson, et al., 2004) 10005004
Coded as asymptomatic bacteriuria 8 (Manges, Johnson, et al., 2004) 10006001
Coded as asymptomatic bacteriuria 9 (Manges, Johnson, et al., 2004) 10012007
Coded as asymptomatic bacteriuria 10 (Manges, Johnson, et al., 2004) CLSC 36 O1:H42; isolated from a patient with cystitis; coded as UTI 1 (Manges et al., 2018) MSHS 100 O2:H7; isolated from a patient with cystitis; coded as UTI 2 (Manges et al., 2018) MSHS 1,070 Isolated from a patient with cystitis; coded as UTI 3 (Manges et al., 2018) MSHS 233 O9:H32; isolated from a patient with cystitis; coded as UTI 4 (Manges et al., 2018) MSHS 434 O73:H18; isolated from a patient with cystitis; coded as UTI 5 (Manges et al., 2018) MSHS 472 O82:NM; isolated from a patient with cystitis; coded as UTI 6 (Manges et al., 2018) MSHS 635 Isolated from a patient with cystitis; coded as UTI 7 (Manges et al., 2018) MSHS 637 Isolated from a patient with cystitis; coded as UTI 8 (Manges et al., 2018) MSHS 689 Isolated from a patient with cystitis; coded as UTI 9 (Manges et al., 2018) MSHS 415 O6:H1; isolated from a patient with cystitis; coded as UTI 10 (Manges et al., 2018) MSHS 133 O24:NM; isolated from a patient with cystitis; coded as UTI 11 (Manges et al., 2018) MSHS 769 O4:H5; isolated from a patient with cystitis; coded as UTI 12 (Manges et al., 2018) UTI PI 486 O11:Neg; isolated from a patient with pyelonephritis; coded as UTI 13 (Manges, Dietrich, et al., 2004) UTI PI 141 X19; isolated from a patient with pyelonephritis; coded as UTI 14 (Manges, Dietrich, et al., 2004) UTI PI 147 Isolated from a patient with cystitis; coded as UTI 15 (Manges, Dietrich, et al., 2004) UTI PI 192 Isolated from a patient with cystitis; coded as UTI 16 (Manges, Dietrich, et al., 2004) UTI PI 240 Isolated from a patient with cystitis; coded as UTI 17 (Manges, Dietrich, et al., 2004) UTI PI 247 Isolated from a patient with cystitis; coded as UTI 18 (Manges, Dietrich, et al., 2004) UTI PI 259 Isolated from a patient with cystitis; coded as UTI 19 (Manges, Dietrich, et al., 2004) UTI PI 268 Isolated from a patient with cystitis; coded as UTI 20 (Manges, Dietrich, et al., 2004) UTI PI 280 Isolated from a patient with cystitis; coded as UTI 21 (Manges, Dietrich, et al., 2004) UTI PI 374 O18; isolated from a patient with cystitis; coded as UTI 22 (Manges, Dietrich, et al., 2004) (Continues) follows: PRJNA551561 (cystitis 1), PRJNA551565 (cystitis 6), and PRJNA551566 (cystitis 11).
| Preparation of whole-cell lysates and outer membrane fractions
Bacteria were grown in N-minimal medium until mid-exponential phase and normalized to an OD 595nm of 0.5. For whole-cell lysate samples, bacterial cells were pelleted and resuspended in 1/10 volume of 2X ESB (Thomas et al., 2005) . Outer membrane fractions were isolated as follows: bacterial cultures were centrifuged at 3, 600 g for 10 min, and pellets were resuspended in 1.5 ml low-salt buffer (100 mM NaPi buffer [pH 7], 5 mM EDTA, and 10% glycerol). Samples were supplemented with 10 µl PMSF and sonicated. Samples were then centrifuged at 3,600 g for 10 min. Supernatants were collected and centrifuged at 100,000 g for 30 min at 4°C. Pellets were resuspended in 2 ml sarcosyl buffer (10 mM Tris [pH 7.5], 5 mM MgCl 2 , and 2% sarcosyl) and incubated for 30 min at 10°C. Samples were then centrifuged for 60 min at 100,000 g, and the pellet containing outer membranes was resuspended in buffer (20 mM Tris-HCl pH 7.5 and 10% glycerol). Outer membrane samples were combined 1:1 with 2X ESB and boiled for 10 min prior to loading samples on an SDS-PAGE gel.
| Western blotting
Whole-cell lysate and outer membrane fractions were resolved on a 10% SDS-PAGE gel and transferred to a polyvinylidene fluoride membrane. Membranes were blocked for 1 hr in Tris-buffered saline (TBS) supplemented with 5% skim milk, and OmpT was detected using the polyclonal anti-CroP antibody as described in Thomassin, Brannon, Gibbs, et al. (2012) . Membranes were washed extensively with TBS and incubated for 1 hr with a goat anti-rabbit secondary antibody conjugated with HRP. Membranes were washed and developed using chemiluminescent HRP substrate.
Strains Description Source
UTI PI 20 Isolated from a patient with cystitis; coded as UTI 23 (Manges, Dietrich, et al., 2004) UTI PI 116 Isolated from a patient with cystitis; coded as UTI 24 (Manges, Dietrich, et al., 2004) W26653 O15; isolated from a patient with sepsis; coded as sepsis 1 (Manges et al., 2006) W55291 O77; isolated from a patient with sepsis; coded as sepsis 2 (Manges et al., 2006) X19714 O86; isolated from a patient with sepsis; coded as sepsis 3 (Manges et al., 2006) X37350 O73; isolated from a patient with sepsis; coded as sepsis 4 (Manges et al., 2006) X47726 O11; isolated from a patient with sepsis; coded as sepsis 5 (Manges et al., 2006) S49894 O102; isolated from a patient with sepsis; coded as sepsis 6 (Manges et al., 2006) H15 O153; isolated from a patient with sepsis; coded as sepsis 7 (Manges et al., 2006) F46700 Isolated from a patient with sepsis; coded as sepsis 8 (Manges et al., 2006) F55268 Isolated from a patient with sepsis; coded as sepsis 9 (Manges et al., 2006) M32569 Isolated from a patient with sepsis; coded as sepsis 10 (Manges et al., 2006) M4026 Isolated from a patient with sepsis; coded as sepsis 11 (Manges et al., 2006) M49611 Isolated from a patient with sepsis; coded as sepsis 12 (Manges et al., 2006) CFT073 (Johnson & Stell, 2000) iutA_r CGTCGGGAACGGGTAGAATCG Multiplex PCR (Johnson & Stell, 2000) fimH_f TGCAGAACGGATAAGCCGTGG Multiplex PCR (Johnson & Stell, 2000) fimH_r GCAGTCACCTGCCCTCCGGTA Multiplex PCR (Johnson & Stell, 2000) papAH_f ATGGCAGTGGTGTCTTTTGGTG Multiplex PCR (Johnson & Stell, 2000) papAH_r CGTCCCACCATACGTGCTCTTC Multiplex PCR (Johnson & Stell, 2000) papC_f GTGGCAGTATGAGTAATGACCGTTA Multiplex PCR (Johnson & Stell, 2000) papC_r ATATCCTTTCTGCAGGGATGCAATA Multiplex PCR (Johnson & Stell, 2000) papEF_f GCAACAGCAACGCTGGTTGCATCAT Multiplex PCR (Johnson & Stell, 2000) papEF_r AGAGAGAGCCACTCTTATACGGACA Multiplex PCR (Johnson & Stell, 2000) sfaS_f GTGGATACGACGATTAACTGTG Multiplex PCR (Johnson & Stell, 2000) sfaS_r CCGCCAGCATTCCCTGTATTC Multiplex PCR (Johnson & Stell, 2000) fyuA_f TGATTAACCCCGCGACGGGAA Multiplex PCR (Johnson & Stell, 2000) fyuA_r CGCAGTAGGCACGATGTTGTA Multiplex PCR (Johnson & Stell, 2000) kpsMII_f GCGCATTTGCTGATACTGTTG Multiplex PCR (Johnson & Stell, 2000) kpsMII_r CATCCAGACGATAAGCATGAGCA Multiplex PCR (Johnson & Stell, 2000) kpsMIII_f TCCTCTTGCTACTATTCCCCCT Multiplex PCR (Johnson & Stell, 2000) kpsMIII_r AGGCGTATCCATCCCTCCTAAC Multiplex PCR (Johnson & Stell, 2000) cnf−1_f AAGATGGAGTTTCCTATGCAGGAG Multiplex PCR (Johnson & Stell, 2000) cnf−1_r CATTCAGAGTCCTGCCCTCATTATT Multiplex PCR (Johnson & Stell, 2000) hlyA_f AACAAGGATAAGCACTGTTCTGGCT Multiplex PCR (Johnson & Stell, 2000) hlyA_r ACCATATAAGCGGTCATTCCCGTCA Multiplex PCR (Johnson & Stell, 2000) ompT_mf (Clermont et al., 2000) chuA_r TGCCGCCAGTACCAAAGACA Phylogenetic typing (Clermont et al., 2000) yjaA_f TGAAGTGTCAGGAGACGCTG Phylogenetic typing (Clermont et al., 2000) yjaA_r ATGGAGAATGCGTTCCTCAAC Phylogenetic typing (Clermont et al., 2000) TSPE4.C2_f GAGTAATGTCGGGGCATTCA Phylogenetic typing (Clermont et al., 2000) TSPE4.C2_r CGCGCCAACAAAGTATTACG Phylogenetic typing (Clermont et al., 2000) ompT_cf 
| Plasminogen activation assay
Bacteria were grown in N-minimal medium to mid-exponential phase and normalized to an OD 595nm of 0.5. Bacterial cells were pelleted and resuspended in ½ volume of phosphate-buffered saline (PBS;
final 6 x10 8 CFU/mL). In a 96-well plate, 178 μL of bacteria and 20 μL of 45 mM VLKpNA (Sigma-Aldrich) were combined. Baseline assays were performed at OD 405nm . After 5 min, 4 μg of plasminogen substrate was added and absorbance (405 nm) was measured every 10 min for 400 min at 37°C with agitation before every reading.
| Proteolytic cleavage of AMPs
Bacteria were grown in N-minimal medium to mid-exponential phase, washed, and normalized to an OD 595nm of 0.5 in PBS. Aliquots of bacteria (10 7 CFU) were combined 1:4 (v/v) with 2 μg/µL LL-37, mCRAMP, C18G or Magainin II (BioChemia), or 1 μg/µL RNase 7 and incubated at room temperature for various time points. Bacteria were separated from peptide cleavage products by centrifugation, and supernatants were combined 1:1 with 2X ESB, then boiled and frozen at −20°C. Peptide cleavage products were resolved on 10%-20% Tris-Tricine gels (Bio-Rad), and RNase 7 samples were resolved on 20% SDS-PAGE gels. Peptides were fixed in the gel by incubation in 20% (v/v) glutaraldehyde for 30 min; gels were rinsed with water and peptides stained for 1h with Coomassie blue G-250 stain. Gels were destained in 20% (v/v) acetic acid.
| Circular dichroism spectroscopy
Experiments were performed on a Jasco J-810 spectropolarimeter (Easton, MD). AMPs (200 µg/ml in PBS) were placed in a quartz cuvette with a path length of 0.1 cm, and spectra were recorded from 260 to 195 nm. Samples were scanned three times at 20°C using a bandwidth of 1 nm, a time response of 2 s, and a scan rate of 100 nm/min. Spectra were corrected by subtracting the background spectrum of PBS, and values were converted from ellipticity to mean residue ellipticity (MRE; degree × cm 2 × dmol −1 ).
| Statistical analyses
Data were analyzed using GraphPad Prism software. Normality was verified using the D'Agostino-Pearson normality test. Fisher's exact test was performed to compare incidence of virulence genes within severity groups of UPEC clinical isolates. FRET activity was assessed using a two-way ANOVA with Tukey's post hoc test. P value ≤ 0.05 was considered significantly different.
| RE SULTS

| Phylogenetic and virulence profile of UPEC isolates
UPEC isolates from patients with different disease severities were obtained from the Manges collection (Manges et al., 2018 (Manges et al., , 2001 (Manges et al., , 2006 Manges, Dietrich, et al., 2004; Manges, Johnson, et al., 2004) . Although UPEC strains are heterogeneous, clinical isolates from UTIs predominantly belong to E. coli phylogenetic groups B2 and D (Johnson, Delavari, Kuskowski, & Stell, 2001) .
To confirm that our isolates are generally representative of UPEC clinical strains, we determined the phylogenetic grouping of our 58 clinical isolates categorized into the fecal (n = 12), ABU (n = 10), UTI (cystitis and pyelonephritis, n = 24), and sepsis (n = 12) groups.
Most isolates from the ABU and UTI groups associated with UTIs belong to the phylogenetic group B2 and, to a lesser extent, D (Table 3 ). In contrast, isolates from the sepsis group were predominantly from group D (Table 3) . Finally, isolates from the fecal group had the most variable phylogenetic grouping with 5/12 isolates belonging to phylogenetic groups A and B1 (Table 3) . Overall, this distribution is in agreement with previous reports, showing that UPEC strains mainly belong to E. coli phylogenetic groups B2 and D .
The 58 isolates were further characterized using multiplex PCR to detect 12 recognized UPEC virulence genes (Table 4 ). Our data showed variations consistent with previous studies reporting that UPEC is a heterogeneous pathotype (Marschall et al., 2012; Maynard et al., 2004; Norinder et al., 2012; Poey, Albini, Saona, & Lavina, 2012) . The fimH gene, involved in UPEC adherence, was present in all but 2 ABU isolates (Table 4 ). There was a difference in the distribution of virulence genes fyuA and ompT for which the incidence was significantly higher in symptomatic (i.e., UTI and sepsis) groups than asymptomatic (i.e., fecal and ABU) groups (Table 4 ). No other genes showed a significant difference in incidence between asymptomatic and symptomatic groups. In agreement with previous studies, we found that ompT is present in (Thomassin, Brannon, Gibbs, et al., 2012) ompT_qr ACCCGATTCCATGCGCCTTCA qPCR (Thomassin, Brannon, Gibbs, et al., 2012) 
| Variability of omptin proteolytic activities among UPEC isolates
OmpT preferentially cleaves substrates between two consecutive basic residues (Dekker, Cox, Kramer, & Egmond, 2001; McCarter et al., 2004) . Therefore, to assess OmpT proteolytic activity we measured cleavage of a FRET substrate (2Abz-SLGRKIQI-K(Dnp)-NH 2 ) that contains a dibasic motif in its center (Brannon, Burk, et al., 2015; Brannon et al., 2013; McPhee et al., 2014; Thomassin, Brannon, Gibbs, et al., 2012) . Cleavage of the substrate by the 58 clinical E. coli isolates was monitored by measuring fluorescence emission over time and compared with substrate cleavage by the previously characterized reference UPEC strain CFT073 (Brannon et al., 2013) . As shown in Figure 1a , omptin activity of the isolates was heterogeneous between groups. Isolates for which the ompT gene was not detected by PCR showed basal activity levels (red triangles in Figure 1a ), whereas isolates harboring the ompT gene showed a wide range of omptin activity. The omptin activity of the isolates of the fecal group was significantly lower than that of the 2 symptomatic groups (UTI and sepsis) ( Figure 1a ). The mean activity of the isolates from the fecal group (0.75 ± 0.5) was lower than that of strain CFT073. In contrast, the activity means of the symptomatic groups (1.54 ± 0.66 and 1.71 ± 0.66) were higher than those of CFT073. Extensive variability in omptin activity was also observed within groups (Figure 1a ). The UTI group exhibited the most heterogeneous omptin activity, and some isolates from the UTI group had threefold higher omptin activity than CFT073. Together, these results indicate that omptin activity is variable among fecal and UPEC clinical isolates.
| OmpT-like proteases in UPEC
In addition to the chromosomally encoded ompT gene, plasmidborne ompT-like genes ompP and arlC are present in several E. coli strains (Kaufmann et al., 1994; McPhee et al., 2014; Zhuge et al., 2018) . These OmpT-like proteins are approximately 74% identical to OmpT. To determine whether the presence of ompT-like genes in some isolates may account for the heterogeneity of OmpT activity observed in Figure 1a , multiplex PCR screens were performed to detect ompT, ompP, and arlC. The ompP gene was not detected in any of the isolates (data not shown). In contrast, the arlC gene was present in 8 of the 58 isolates ( Figure 1b ). Strikingly, arlC was only present in symptomatic isolates, which was statistically significant according to Fisher's exact test (p = .0445). Most isolates harboring the arlC gene also contained ompT and generally had higher proteolytic activity (green circles, Figure 1a ) than CFT073. This is consistent with the report that ArlC cleaves the FRET substrate (McPhee et al., 2014) . Isolate 18 from the UTI group did not have ompT but harbored arlC (Figure 1b ); this isolate exhibited moderate proteolytic activity (purple triangle, Figure 1a ). Together, these data show that among commensal and clinical isolates, higher omptin activity is associated with symptomatic disease and isolates with the greatest omptin activity harbor both the ompT and arlC genes.
| Variability of ompT and arlC expression among select UPEC cystitis isolates
To further understand omptin activity among UPEC isolates, we selected 12 isolates from the UTI group (Table 1) for further analysis because they have the most heterogeneous omptin activity.
The presence of ompT genes in these isolates was confirmed by Southern blot analysis (Figure 2a ). This analysis also indicated that two ompT genes may be present in isolates 7, 8, and 11. Consistent with the multiplex PCR results, arlC was detected in UTI isolates 1, 6, and 11 ( Figure 2a ). Next, qPCR was used to measure the expression levels of ompT and arlC. In agreement with our activity assay, ompT transcript levels were heterogeneous among these UTI isolates ( Figure 2b and c). Only three isolates (2, 10, and 11) had similar expression levels to the reference strain CFT073, whereas all other isolates had higher ompT expression levels than the reference strain. As expected from the multiplex PCR screen and Southern blot, arlC expression was only detected in UTI 1, 6, and 11 isolates. UTI isolates 1 and 6, which showed the highest ompT and arlC expression levels, also had the highest omptin activity levels ( Figure 2c ). Although both ompT and arlC are present in UTI isolate 11, they have low expression levels, which is consistent with the low omptin activity observed ( Figure 2c ). These data indicate that heterogeneous omptin activity levels are associated with both the presence and the different expression levels of the ompT and arlC genes.
| arlC is present on plasmids
To determine the genomic context of the ompT and arlC genes, isolates 1, 6, and 11 of the UTI group were sequenced on a PacBio platform. These isolates were then renamed cystitis 1, cystitis 6, and cystitis 11. Detailed descriptions of genomes and gene fea- Tables A1-A7 ).
In all three isolates, ompT was located within the bacterial chromo- from triplicate samples. Bars represent mean ± SD fold change in fluorescence for each group. Bacteria that contain the ompT gene are indicated by circles, and those that do not contain ompT are indicated by triangles. Indicated in green or purple are isolates that contain arlC. Statistical analysis was performed by one-way ANOVA followed by Tukey's post hoc test using GraphPad Prism software (NS, not significant; *p ≤ 0.05; **p ≤ 0.01). (b) Multiplex PCR of arlC (852 bp), ompT (670 bp), and fimH (508 bp) from each of the clinical isolates. Amplification of fimH was used as a positive control. Numbers indicate isolate number for each group. Data are representative of at least three independent experiments
| Comparative analysis of OmpT, OmpP, and ArlC
With the unexpected detection of arlC among the UPEC clinical isolates, we hypothesized that the presence of a second or even a third omptin protease within a single species may provide an advantage by expanding the potential range of substrates cleaved. Therefore, we sought to compare the substrate specificities of these proteases.
As OmpT undergoes autocleavage during purification (Kramer, Zandwijken, Egmond, & Dekker, 2000; Vandeputte-Rutten et al., 2001 ) and mutagenesis of residues to stabilize the protein results in a significant decrease in FRET substrate cleavage ((Kramer et al., 2000) ; unpublished data Thomassin JL and Brannon JR), it was not possible to purify these proteases and directly compare their activities. Instead, we produced OmpT, OmpP, and ArlC in E. coli BL21, a laboratory strain that lacks omptin proteases. To test their production and correct localization in BL21, omptin proteins were detected by Western blot analysis from both whole cells and outer membrane . Data are representative of at least three independent experiments preparations ( Figure 4a ). To determine whether the proteases were active in BL21, FRET substrate cleavage was monitored over time.
As expected, BL21 with empty vector did not cleave the FRET substrate, whereas the three omptins readily cleaved the FRET substrate ( Figure 4b ). This demonstrates that when produced in BL21, ArlC, OmpP, and OmpT are found in the outer membrane and are proteolytically active.
Omptin proteases are generally subdivided into OmpT-like or Pla-like subfamilies. These subfamilies differ in their ability to cleave plasminogen to activate it into active plasmin, with Pla-like omptins producing active plasmin more readily than OmpT-like omptins (Haiko et al., 2009; Kukkonen et al., 2001) . To verify that the three omptin proteases belong in the OmpT-like subfamily, we tested their ability to cleave plasminogen into plasmin. Consistent with their presence in the outer membrane, all three omptins cleaved plasminogen to a greater extent than BL21 alone ( Figure 4c ). There was no difference in their ability to activate plasminogen. Compared with the positive control, Pla produced in BL21, the E. coli omptins converted significantly less plasminogen into plasmin. These data are consistent with previous publications (Brannon, Burk, et al., 2015; Kukkonen et al., 2001; McPhee et al., 2014) and suggest that all three omptins found in E. coli belong to the OmpT-like subfamily of omptin proteases.
Omptin proteases belonging to the OmpT-like subfamily have been associated with AMP cleavage (Le Sage et al., 2009; Stumpe et al., 1998; Thomassin, Brannon, Gibbs, et al., 2012) . Previous work has shown that OmpT from EPEC, EHEC, and UPEC cleaves the human cathelicidin LL-37. Although ArlC was shown to play a role in AMP resistance (McPhee et al., 2014) , and OmpT and OmpP are reported to exhibit similar substrate specificities (Hwang et al., 2007; McCarter et al., 2004) , their ability to cleave different AMPs has not been directly compared. Therefore, we investigated the ability of the E. coli omptins to cleave the synthetic cationic peptide C18G and various cathelicidins Magainin II (Xenopus laevis), mCRAMP (Mus musculus), and LL-37 (Homo sapiens). As expected, AMPs incubated with BL21 did not show any degradation or cleavage products, indicating that BL21 does not contain intrinsic proteases that cleave these AMPs (Figure 5a ). OmpT cleaved all peptides by the first time point tested (2 min C18G, 15 min mCRAMP, Magainin II, and LL-37; Figure 5a ). Similar to OmpT, OmpP readily cleaved C18G and Magainin II within 2 and 30 min, respectively.
In contrast, OmpP only cleaved small amounts of mCRAMP after 60 min and did not appear to cleave LL-37 ( Figure 5a ). ArlC cleaved mCRAMP, C18G, and Magainin II by the first time point tested (2 min C18G, 15 min mCRAMP, and Magainin II), but only a small amount of LL-37 cleavage was observed after 60 min. Substrate properties, such as size and secondary structure, are known to influence omptin activity (Brannon, Thomassin, Gruenheid, & Le Moual, 2015; Hritonenko & Stathopoulos, 2007) . Peptide secondary structure also influences omptin activity ; therefore, we used circular dichroism spectroscopy to determine the secondary structure of these AMPs (Figure 5c ).
Under our experimental conditions, only LL-37 is α-helical, while mCRAMP, C18G, and Magainin II are unstructured ( Figure 5c ).
While peptide structure did not affect OmpT activity, ArlC did not appear to cleave the only α-helical AMP, LL-37 (Figure 5b ,c).
Together, these findings suggest that OmpT, OmpP, and ArlC have differences in substrate specificities.
We previously reported that disulfide bonds present in defensins render them resistant to OmpT-mediated proteolysis (Thomassin, Brannon, Kaiser, et al., 2012) . Yet ArlC was shown to contribute to bacterial survival in the presence of human defensins (McPhee et al., 2014) , suggesting that unlike OmpT, ArlC might cleave AMPs that are stabilized by disulfide bridges. RNase 7 contains four disulfide bridges and three dibasic sites (Figure 6a ) and is abundant in the urinary tract (Spencer et al., 2011 (Spencer et al., , 2013 . The presence of dibasic sites suggests that RNase 7 might be an omptin substrate; therefore, we sought to investigate whether there was a difference in omptin-mediated F I G U R E 3 Genomic context of arlC and ompT. Schematic representation of the genomic contexts of the ompT (a) and arlC (b) genes in cystitis isolates 1, 6, and 11. Genomic contexts of ompT (a) and arlC (b) from respective reference strains CFT073 (a) and NRG857c (b) are included for comparison. Omptin genes are indicated in dark gray, light gray indicates genes located upstream and downstream of the omptin genes, stripes indicate pseudogenes, and black lines indicate intergenic space cleavage of this peptide. Under our experimental conditions, OmpT and OmpP did not cleave RNase 7 (Figure 6b) . After a 60-min incubation with ArlC, an RNase 7 cleavage product appeared, with more cleavage product appearing after 90 min. While cleavage appears limited, ArlC was the only OmpT-like omptin able to cleave RNase 7.
Taken together, these data indicate that ArlC, OmpP, and OmpT have different substrate specificities, suggesting that the presence of multiple omptin proteases in a single bacterial strain may enhance AMP resistance by increasing the range of substrates cleaved.
| D ISCUSS I ON
Detection of specific genes, including ompT, is often used to characterize virulent clinical UPEC isolates Najafi et al., 2018) . Previous studies have suggested that OmpT from the UPEC strain CFT073 is involved in adhesion, invasion, and/or inactivation of AMPs (Brannon et al., 2013; He et al., 2015) . While the presence of ompT is associated with virulent strains, its precise contribution remains unclear, as UPEC clinical isolates have highly variable genetic sequences (Schreiber et al., 2017) . In addition, we previously observed large differences in OmpT protein activity due to differential ompT expression (Thomassin, Brannon, Gibbs, et al., 2012; Thomassin, Brannon, Kaiser, et al., 2012) , suggesting that the presence of the ompT gene may not entirely correlate with its activity levels in different UPEC clinical isolates. In this study, we hypothesized that OmpT activity correlates with increased disease severity among UPEC clinical isolates. To test this hypothesis, we systematically measured omptin activity in 58 E. coli isolates representing colonization and a range of clinical outcomes. Increased omptin activity was correlated with clinical UPEC strains isolated from patients with symptomatic UTIs (UTI and sepsis groups).
Omptin activity was heterogeneous among the clinical isolates and could be related to differential ompT expression and the presence of a second OmpT-like protease, arlC. For example, a 20-fold difference in ompT expression was observed between isolates 5 and 11 of the UTI group (Figure 2b) . This finding is not unprecedented, since it was previously shown that ompT expression was 32-fold higher in EHEC than in EPEC (Thomassin, Brannon, Gibbs, et al., 2012) . Differential ompT expression levels in EHEC and EPEC were attributed to differences in distal promoter sequences found more than 150 bp upstream of the ompT start codon (Thomassin, Brannon, Gibbs, et al., 2012 ). An EPEC-like ompT distal promoter F I G U R E 4 ArlC, OmpP, and OmpT are functional in BL21. (a) BL21 containing empty vector (ø) or plasmids encoding arlC, ompP, or ompT were grown until mid-log phase and normalized to OD 595 0.5. Proteins from whole-cell preparations or isolated bacterial outer membranes were resolved by SDS-PAGE and transferred to a PVDF membrane. Omptins were detected by Western blot using anti-CroP polyclonal antibodies. the presence of different surface structures prevent the peptide from accessing the OmpT active site as described by Galvàn and colleagues (Galvan, Lasaro, & Schifferli, 2008) , and (d) another explanation for heterogeneous omptin activity observed in this study could be attributed to the presence of a second plasmid-encoded omptin, ArlC, in some isolates. The arlC gene was first identified as part of a large virulence plasmid of the AIEC strain NRG857c (McPhee et al., 2014) . BLAST searches in the NCBI database revealed that arlC can also be found on plasmids harbored by various human ExPEC strains isolated from patients with meningitis and sepsis, as well as avian E. coli strains ( Figure A2b ). Specifically, tBLASTn search of the nonredundant plasmid database identified arlC in 91 instances (Galata et al., 2018) . The arlC gene is predominantly found in IncFIB (41/91) or IncFII (28/91) plasmids and less commonly in IncFIC(FII), IncQ1, IncN, or IncHI2 plasmids (13/91, 6/91, 2/91, 1/91, respectively). While we did not detect ompP in our study, ompP is present in some UPEC strains that were collected and sequenced by the Broad Institute (E.coli UTI Bacteremia Initiative, 2019). This opens the possibility that any combination of ompT-like omptin may be present in a given UPEC strain. Omptins belonging to the OmpT-like subfamily are known to have subtle differences in substrate specificity Hwang et al., 2007; McCarter et al., 2004) . Studies using peptide libraries to compare OmpP and OmpT activity showed both omptins preferentially cleave substrates between two consecutive basic residues, but that OmpP appears to have a slight preference for Lys in the P and P' sites (Hwang et al., 2007) . In addition to subtle differences in amino acid motif preference, peptide size and secondary structure also impact substrate specificity Haiko et al., 2009; Hritonenko & Stathopoulos, 2007) . For example, AMP α-helicity was shown to be a determining factor for proteolytic activity of the OmpT-like omptin, CroP, from Citrobacter rodentium . While ArlC, OmpP, and OmpP all readily cleave small unstructured substrates, such as the FRET substrate and C18G, differences in cleavage efficiency were noted for larger or more structured AMPs. As all three proteases readily cleave the FRET substrate and C18G, the striking differences in ability to cleave Magainin II, mCRAMP, and LL-37 are likely due to intrinsic differences between OmpT, OmpP, and ArlC. OmpP did not cleave Magainin II as efficiently as C18G and did not cleave larger substrates such as mCRAMP, LL-37, and RNase 7 (Figures 4a, 5a,b,   6b ). These findings suggest that larger peptides might be excluded from the OmpP active site. While OmpT and ArlC cleaved the FRET substrate, C18G, Magainin II, and mCRAMP relatively efficiently, there was a striking difference in LL-37 and RNase 7 cleavage (Figures 4a, 5a, and 6b ). Given the similarity in size of mCRAMP and LL-37, and the ability of ArlC to cleave RNase 7, it is unlikely that the 3 amino acid size difference accounts for the marked difference in cleavage efficiency. It is possible that ArlC does not cleave α-helical AMPs, but instead cleaves unstructured and disulfide bond-stabilized peptides. While this possibility requires further study, it is supported by the finding that an arlC deletion strain is more susceptible to killing by human defensins (McPhee et al., 2014) . Altogether, these findings suggest the presence ArlC and OmpT in the same UPEC isolate may confer a fitness advantage by expanding the spectrum of target substrates.
| CON CLUS IONS
Here, we show that increased omptin activity is associated with UPEC strains causing symptomatic UTIs. Extensive heterogeneity of omptin activity among UPEC clinical isolates was due to variations in ompT expression and due to the presence of a plasmid-encoded ompT-like gene arlC. Our findings support current profiling practices of UPEC strains that include the ompT gene (Johnson & Stell, 2000) , but suggest that additional screening for arlC should be considered as both genes were exclusively harbored in UPEC strains associated with symptomatic infections. Altogether, our findings suggest that the presence of two different omptins in a UPEC strain may provide an additional fitness advantage by expanding the range of AMPs cleaved during UTIs. Sagan for the gift of labeling reagents for Southern hybridization. We thank Drs. Olivera Francetic and Yannick Tremblay for helpful comments and suggestions. We gratefully acknowledge Mr. Gary Leveque from the McGill University and Genome Québec Innovation Center for his assistance with plasmid sequence assembly.
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R E FE R E N C E S
M ATER I A L S A N D M E TH O DS G EN O M E A N A LYS I S
Sequenced genomes were annotated using PATRIC (Wattam et al., 2017) . Isolate serotypes were determined using the online database SeroTypeFinder (Joensen, Tetzschner, Iguchi, Aarestrup, & Scheutz, 2015) . Strain sequence type was determined using the MLST2 server (Larsen et al., 2012) , and plasmids were typed using the pMLST 2.0 server (Carattoli et al., 2014) . Pathogenicity islands were detected using IslandViewer 4 (Bertelli et al., 2017) and VRprofile 2 .
Antibiotic resistance genes were identified in PATRIC, IslandViewer 4, (ompT, fimH, iutA, papA, papH, papC, papF, fyuA, kpsMTII, papE, sfaS, kpsMTIII, were used as subject sequences for a multiple sequence alignment of the indicated UPEC strain genome using BRIGs software. Black fill indicates no homology F I G U R E A 2 Comparison of plasmid sequences containing pathogenicity island 6. (a) Plasmids from the indicated cystitis (UTI) isolates were used as subject sequences in multiple sequence alignments with the indicated plasmid containing pathogenicity island 6 from pO83 from E. coli NRG857c using BRIGs software. White fill indicates no homology. (b) Coding sequences for pathogenicity islands (PI-) 1, 2, 3, 4, 5, and 6 from pO83 (indicated) were used as subject sequences for a multiple sequence alignment with the indicated plasmid nucleotide sequence using BRIGs software. Black fill indicates no homology 
